[关键词]
[摘要]
目的 探讨双歧杆菌联合美沙拉嗪对溃疡性结肠炎的疗效观察。方法 选取2008年1月—2018年1月于北京市丰台区南苑医院消化内科诊治的306例溃疡性结肠炎患者,采用随机数字法分为对照组和观察组,每组各153例。对照组患者给予美沙拉嗪肠溶片,1.0 g/次,3次/d。观察组患者在对照组基础上联合双歧杆菌三联活菌胶囊,2粒/次,2次/d。两组患者均接受8周治疗。比较两组患者的临床疗效和不良反应发生率,并测定两组治疗前后Azzolini内镜评分、Mayo评分、C反应蛋白(CRP)、白介素-6(IL-6)、纤维蛋白原(FIB)及血小板计数(PLT)。结果 治疗后,观察组患者临床治疗有效率为90.20%,对照组有效率为75.16%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的Azzolini内镜评分、Mayo评分、CRP、IL-6、FIB及PLT均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组患者的Azzolini内镜评分、Mayo评分、CRP、IL-6、FIB及PLT均显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗期间,观察组患者不良反应发生率为5.88%,对照组患者的不良反应发生率为3.92%,差异均无统计学意义。结论 双歧杆菌三联活菌胶囊联合美沙拉嗪肠溶片能够显著改善溃疡性结肠炎的临床症状及凝血功能,并降低炎性反应,安全性较好。
[Key word]
[Abstract]
Objective To investigate the clinical effect of bifidobacterium combined with mesalazine in treatment of ulcerative colitis. Methods Patients (306 cases) with ulcerative colitis in gastroenterology department of Beijing Nanyuan Hospital from January 2008 to January 2018 were divided into control group and observation group according to the random number method, and each group had 153 cases. Patients in the control group was given Mesalazine Enteric Coated Tablets, 1.0 g/time, three times daily. Patients in the observation group was given Bifidobacterium Triple Live Capsules on the basis of control group, 2 grains/time, twice daily. Patients in two groups were treated for 8 weeks. The clinical treatment effect and the incidence of the adverse reaction in two groups were compared, and the Azzolini endoscopic and Mayo scores, the levels of CRP, IL-6, FIB, and PLT in two groups before and after treatment were measured. Results After treatment, the effective rate of clinical effect in the observation group was 90.20%, the effective rate in the control group was 75.16%, the difference was statistically significant (P<0.05). After treatment, Azzolini endoscopy score, Mayo score, CRP, IL-6, FIB and PLT levels in two groups were significantly decreased, and there was significant difference before and after treatment in the same group (P<0.05). And the Azzolini endoscopic score, Mayo score, CRP, IL-6、FIB and PLT in the observation group were significantly lower than those in the control group, the difference was statistically significant (P<0.05). During the treatment, the incidence of the adverse drug reaction in the observation group was 5.88%, and the incidence of the adverse drug reaction in the control group was 3.92%, the differences were not statistically significant. Conclusion Bifidobacterium Triple Live Capsules combined with Mesalazine Enteric Coated Tablets in treatment of ulcerative colitis can siginificantly improved the clinical symptoms and coagulation function, and decreased the inflammatory reaction, with good safety.
[中图分类号]
[基金项目]